Proactive Research analyst Emma Ulker discusses MaxCyte Inc's (LON:MXCT) first half trading update in which it revealed revenues grew by 30% to US$10.9mln and that its research and development operation's expected to be self-funded by the end of the year. Ulker says trading reflected the solid progress made in their cell therapy business which is focused on driving adoption of its non-viral cell engineering technology Flow Electroporation across its ExPERT instrument platform.
15 Jul 20